Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), which was approved by the National Medical Products Administration (NMPA) of China in 2018 for the third-line treatment of non-small cell lung cancer (NSCLC). Here, for the first time, the longitudinal pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ting, An, Zhuoling, Sun, Yongkun, Wang, Xunqiang, Du, Ping, Li, Pengfei, Chi, Yihebali, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689013/
https://www.ncbi.nlm.nih.gov/pubmed/33282726
http://dx.doi.org/10.3389/fonc.2020.548300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689013/
https://www.ncbi.nlm.nih.gov/pubmed/33282726
http://dx.doi.org/10.3389/fonc.2020.548300

Ejemplares similares